imgs-04.png

Anthony A. Curro, MBA
Chief Executive Officer

Anthony Curro
Chief Executive Officer

Anthony is a seasoned business executive and entrepreneur, with over 25 years of experience in life sciences, technology, & finance. Prior to joining Immplacate, Anthony was CEO at Spruce Technology, where he led the firm through an extended period of high growth and expansion. In addition, he has held a number of senior level positions with global responsibilities, which include the medical device powerhouse Guidant, where he was involved in various aspects of the cardiovascular portfolio of products. Anthony also serves on the board at Xylyx, Inc., a leading biotechnology firm that specializes in native extracellular matrix (ECM) products for life sciences. He has specialized capabilities in sales, marketing, finance, operations, HR, R&D, and strategy. Anthony holds an MBA from Columbia Business School, Columbia University in New York.

imgs-03.png

Holly Wobma, MD, PhD
Director, Research & Innovation
Scientific Co-Founder

Holly Wobma
Research Director, Scientific Co-Founder

Holly has been involved in biomedical research for 12 years. She recently completed an MD-PhD in Biomedical Engineering at Columbia University on a Presidential Scholarship. She has devoted her research to developing mesenchymal stromal cell immunotherapies and has expertise in cell therapies, immune modulation, and transplant tolerance. Prior to her MD-PhD, she worked in a stem cell manufacturing lab and has also conducted research in cancer nanotherapeutics. She graduated at the top of her college class at the University of Calgary (Canada), receiving the Muriel Kovitz Prize.

Beyond research, Holly has been engaged in the stem cell field for 5 years as a science writer, contributing monthly articles about the latest developments in regenerative medicine.

seda.png

Seda Ghazaryan, PhD
Lead Scientist, Technology Dev. Officer


Seda Ayer, PhD
Lead Scientist, Technology Dev. Officer

Seda completed her PhD in Cancer Biology in 2009 at the German Cancer Research Center (DKFZ) in Heidelberg, Germany. Since then, she has been on the frontlines of cancer and stem cell research, as both a researcher and an innovator. Most recently, she developed and executed a bio-tech preclinical research project through Rutgers New Jersey Medical School. Her work in cell therapy has since transitioned into a clinical stage project and yielded multiple patent applications.
Her laboratory expertise includes 10+ years of experience in generating in vivo disease and transplant models, including humanized mouse models for cell therapy applications. Seda’s work has been featured in peer reviewed scientific journals where she has authored and co-authored numerous papers.